Aveo, Cytk, Zmgd.pk News Alerts From Pennytobuck.com
Zamage Digital Art Imaging, Inc.s (Pink:ZMGD) subsidiary EverdowCRM Inc
. announces, that the company has published the companys financials for the period of January 1 - June 30, 2010 (Posted on Pink Sheets, Financials section on July 9, 2010). During this period, the company generated total revenues in the amount of $145,000 USD, and profits of $90,000 USD.
ZMGD.pk and its subsidiary Everdow Software (Beijing) Inc. (Wing Road Software Co., Ltd.) focus on delivery of high-tech software solutions in business management industry.
Everdow Software Inc. focuses on business-oriented product development, offering its customers professional, Customer Relationship Management (CRM) systems and easy transaction/information management. Everdow Software Inc. provides reliable software solutions and professional service for various industries (banking, education, manufacturing, etc.). The companys core products include Everdow Online Examination System, Everdow Customer Relationship Management System and Award-winning Everdow Bank Risk Monitoring System.For further information on ZMGD.pk , please visit http://www.zamagedigitalcorp.com For This Article and More Click Here
Cytokinetics, Incorporated (NASDAQ:CYTK) announced today that the National Institute of Neurological Disorders and Stroke (NINDS) has awarded the company a grant in the amount of $2.9 million to support research and development of CK-2017357, a fast skeletal muscle troponin activator, directed to the potential treatment for myasthenia gravis. The grant was awarded to Cytokinetics under the American Recovery and Reinvestment Act of 2009.
NINDS, a division of the National Institutes of Health (NIH), conducts and supports research on brain and nervous system disorders. The mission of the NINDS is to reduce the burden of neurological disease -- a burden borne by every age group, every segment of society, and people all over the world. Created by the U.S. Congress in 1950, NINDS is one of the more than two dozen research institutes and centers that comprise the NIH. The NIH, located in Bethesda, Maryland, is an agency of the Public Health Service within the U.S. Department of Health and Human Services. NINDS has occupied a central position in the world of neuroscience for more than 50 years.
Cytokinetics is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to leverage their expertise in one area, in our case the cytoskeleton and the biology of muscle function, to tackle the pursuit of new treatments for multiple disease areas. However, the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients. That is our goal. For more information on CYTK visit http://www.cytokinetics.com/
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the companys second quarter ended June 30, 2010 will be released before the market opens on Thursday, July 29, 2010. The AVEO management team will host a conference call discussing the companys financial results, recent developments and 2010 guidance on Thursday, July 29, 2010 at 10:00 a.m. (EDT). The call can be accessed by dialing 1-866-788-0543 (domestic) or 1-857-350-1681 (international) five minutes prior to the start of the call and providing the passcode 84967127. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 50571817. The replay will be available for two weeks from the date of the live call.
AVEO Pharmaceuticals (NASDAQ:AVEO) blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The companys lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOs proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at http://www.aveopharma.com.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty-five thousand dollars from a third party for (30) days of advertisement services for ZAMAGE DIGITAL ART (OTC: ZMGD.PK).
by: Bill Pennyman
Watch Takers FREE - Why Pay for the Cinema? You Can Watch it FREE on your PC! Exploring Your Mre Meal Options Practicing Yoga Will Shape The Course Of Your Life In Three Steps Watch Takers Movie - Watch August's Number ONE Movie Erightsoft Super An Easy Way to Turn Your Slow PC Into a Super Fast PC Attracting Many To Anaheim Right Soft Key Reactive or Reflective? The Need For A 24 7 Call Centre How To Fight A Traffic Ticket HOW TO FIND DEEPER TREASURE WITH YOUR METAL DETECTOR Let Your Wall Cladding Go Natural With Natural Stone